NLTX Stock Overview
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Neoleukin Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.96 |
| 52 Week High | US$18.80 |
| 52 Week Low | US$8.11 |
| Beta | 1.1 |
| 1 Month Change | 5.76% |
| 3 Month Change | -0.14% |
| 1 Year Change | 59.51% |
| 3 Year Change | -93.52% |
| 5 Year Change | -66.44% |
| Change since IPO | -94.16% |
Recent News & Updates
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?
Jul 18
Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation
Mar 10Recent updates
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?
Jul 18Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation
Mar 10We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Rate
Nov 19Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?
Jun 03Shareholder Returns
| NLTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.5% | 1.0% | 1.2% |
| 1Y | 59.5% | 0.7% | 24.9% |
Return vs Industry: NLTX exceeded the US Biotechs industry which returned 1.7% over the past year.
Return vs Market: NLTX exceeded the US Market which returned 22% over the past year.
Price Volatility
| NLTX volatility | |
|---|---|
| NLTX Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NLTX's share price has been volatile over the past 3 months.
Volatility Over Time: NLTX's weekly volatility has increased from 44% to 87% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 7 | Donna Cochener-Metcalfe | www.neoleukin.com |
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company’s lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019.
Neoleukin Therapeutics, Inc. Fundamentals Summary
| NLTX fundamental statistics | |
|---|---|
| Market cap | US$32.80m |
| Earnings (TTM) | -US$34.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs NLTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NLTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$34.26m |
| Earnings | -US$34.26m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NLTX perform over the long term?
See historical performance and comparison